Skip to content

Cardiac Resynchronization Therapy Defibrillator Based Impedance Monitoring Study

CRT-D Based Impedance Monitoring Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00500838
Enrollment
75
Registered
2007-07-13
Start date
2007-07-31
Completion date
2008-08-31
Last updated
2019-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Cardiac Resynchronization Therapy, Transthoracic Impedance

Brief summary

The intent of this feasibility study is to collect and analyze intra-thoracic impedance measurements from a CRT-D device in a heart failure population.

Detailed description

This is a multi-center feasibility study intended to collect information on changes in intra-thoracic impedance measurements from CRT-D devices. In order to obtain an intra-thoracic impedance measurement, the device delivers a subthreshold impulse that measures the resistance between two electrodes. At the programmed interval, measurements will be obtained between six different lead configurations.

Interventions

DEVICETransthoracic Impedance

Impedance measures will be automatically collected via the device

Sponsors

Abbott Medical Devices
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Eligible patients will meet all of the following: 1. Have an approved indication per American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines for implantation of a Cardiac Resynchronization Therapy Defibrillator (CRT-D) or have a previously implanted St. Jude Medical (SJM) CRT-D system capable of enabling the diagnostic impedance monitoring feature with implant occurring within the last 14 days 2. Have had at least one hospitalization, emergency department visit, or clinic visit within the past 12 months for treatment of decompensated heart failure requiring intravenous diuretics, intravenous inotropes, Natrecor (Nesiritide) therapy, or an increase in an oral diuretic of ≥100% over a 24 hour period 3. Have the ability to maintain a patient diary for recording daily weights, symptoms related to heart failure, changes in diuretic therapy, and any unscheduled clinic or hospital visits 4. Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed follow-up tests and schedule of evaluation

Exclusion criteria

Patients will be excluded if they meet any of the following: 1. Be less than 18 years of age 2. Have had a recent myocardial infarction, unstable angina or cardiac revascularization within 40 days of enrollment 3. Have had a recent Cerebrovascular Accident or Transient Ischemic Attack within three months of enrollment 4. Have a contraindication for an emergency thoracotomy 5. Have an indication that requires programming device in atrial pacing mode 6. Have permanent (chronic) atrial fibrillation 7. Have a capped or inactive right atrial or right ventricular pacing/defibrillator lead 8. Have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate or short term contact with heparin 9. Be pregnant or planning a pregnancy in the next 6-months 10. Be currently participating in a clinical investigation that includes an active treatment arm 11. Have a life expectancy of less than six months due to any condition

Design outcomes

Primary

MeasureTime frame
To assess the use of the impedance feature in conjunction with other functions of the CRT-D device6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026